Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinical Trial Enrollment

- PMLiVE

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Around 60% of chronic spontaneous urticaria patients are uncontrolled by H1-antihistamines

EU flag

EMA endorses digital measure as primary endpoint in Duchenne muscular dystrophy trials

The decision qualifies SV95C as an alternative to the widely used six-minute walking test

- PMLiVE

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

The company will gain the first refusal to one of Poseida’s clinical stage programmes

- PMLiVE

New study shows AI model can identify where patients’ cancers originated

The predictions from OncoNPC could enable doctors to choose targeted cancer treatments

- PMLiVE

Insight to impact: how insights are shaping medical affairs strategies

By Max Noble

- PMLiVE

MSD and Astex announce expansion to oncology drug discovery collaboration

Astex will receive $35m upfront plus milestone payments totalling $500m per programme

- PMLiVE

Merck and Ginkgo Bioworks enter biologic manufacturing collaboration worth up to $490m

The companies partnered last year to improve Merck's active pharmaceutical ingredient manufacturing

- PMLiVE

New NHS treatments increase survival rates for babies with spinal muscular atrophy

Around 70 babies are born with the rare muscle-wasting disease each year in the UK

- PMLiVE

UK government unveils vaccine development hub to strengthen pandemic defences

The centre will support the development of vaccines against new threats

- PMLiVE

Creating truly effective communications – the impact of high speed, high octane messaging

Navigating the busy omnichannel communication lanes to make the best of digital

- PMLiVE

Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases in the US

dengue fever mosquito

Bavarian Nordic’s chikungunya vaccine candidate shows promise in late-stage trial

There is currently no approved vaccine or specific treatment for chikungunya virus infections

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links